BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Science in Seattle - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Science in Seattle
X-ORIGINAL-URL:https://scienceinseattle.com
X-WR-CALDESC:Events for Science in Seattle
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Vancouver
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20210314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20211107T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20220313T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20221106T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20230312T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20231105T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20210101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20220504T120000
DTEND;TZID=America/Vancouver:20220504T130000
DTSTAMP:20260613T094523
CREATED:20220411T165417Z
LAST-MODIFIED:20220411T165417Z
UID:17417-1651665600-1651669200@scienceinseattle.com
SUMMARY:Cellular Therapy Series Part I: How Engineered Cellular Therapies are Reshaping Medicine
DESCRIPTION:Part 1: Wednesday\, May 4\, 2022\, 12:00 – 1:00 PM\nPart 2: Wednesday\, September 14\, 2022\, 12:00 – 1:00 PM \nCellular therapies are reshaping the therapeutic landscape\, representing one of the highest growth sectors for FDA IND applications\, spurring some of the most recognized young companies\, producing several high-value cancer drugs\, and transforming lives. The Seattle area has led the development from the start with seminal work by Dendreon\, bringing to market the first FDA-approved immunotherapy made from a patient’s own immune cells (Provenge)\, as well as pioneering advances in chimeric antigen receptor (CAR) T cell therapy by the Hutch\, Seattle Children’s Research Institute and Juno Therapeutics. Today the region remains at the forefront\, supporting the development and launch of two commercially available CAR T cell products\, Breyanzi (Juno/Celgene/Bristol Myers Squibb) and Abecma (2seventy bio (formerly bluebird bio)/Celgene/Bristol Myers Squibb)\, and delivering innovative cell therapies to put more patients on the path to a cure. Young cellular therapy companies with roots in Seattle such as\, Sana\, 2seventy bio\, Umoja\, GentiBio\, Notch Therapeutics\, Century Therapeutics\, Gilead\, Sonoma Bio\, Lyell\, among others promise to usher in the next era of innovation. The science is established. The patient benefits are real.  The possibilities are endless. \nPart 1 Focus:\n•  Where we are now—FDA Approved Therapies\n•  How we got here—the science in a broad international sense but specifically highlighting Seattle’s history in the development of cellular therapies.\n•  The history of how these therapies have made it to market. Special challenges this new technology had to face such as manufacturing.\n•  What therapies are currently on the market\n•  Special focus on how current therapies are putting more patients on a path to a cure \nPricing: \n$25 in-person (includes lunch and beverages)\n$10 virtual via zoom
URL:https://scienceinseattle.com/event/cellular-therapy-series-part-i-how-engineered-cellular-therapies-are-reshaping-medicine/
LOCATION:Online
ORGANIZER;CN="Life Science Washington":MAILTO:kaitlyn@lifesciencewa.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20220504T120000
DTEND;TZID=America/Vancouver:20220504T130000
DTSTAMP:20260613T094523
CREATED:20220411T165417Z
LAST-MODIFIED:20220411T165417Z
UID:25875-1651665600-1651669200@scienceinseattle.com
SUMMARY:Cellular Therapy Series Part I: How Engineered Cellular Therapies are Reshaping Medicine
DESCRIPTION:Part 1: Wednesday\, May 4\, 2022\, 12:00 – 1:00 PM\nPart 2: Wednesday\, September 14\, 2022\, 12:00 – 1:00 PM \nCellular therapies are reshaping the therapeutic landscape\, representing one of the highest growth sectors for FDA IND applications\, spurring some of the most recognized young companies\, producing several high-value cancer drugs\, and transforming lives. The Seattle area has led the development from the start with seminal work by Dendreon\, bringing to market the first FDA-approved immunotherapy made from a patient’s own immune cells (Provenge)\, as well as pioneering advances in chimeric antigen receptor (CAR) T cell therapy by the Hutch\, Seattle Children’s Research Institute and Juno Therapeutics. Today the region remains at the forefront\, supporting the development and launch of two commercially available CAR T cell products\, Breyanzi (Juno/Celgene/Bristol Myers Squibb) and Abecma (2seventy bio (formerly bluebird bio)/Celgene/Bristol Myers Squibb)\, and delivering innovative cell therapies to put more patients on the path to a cure. Young cellular therapy companies with roots in Seattle such as\, Sana\, 2seventy bio\, Umoja\, GentiBio\, Notch Therapeutics\, Century Therapeutics\, Gilead\, Sonoma Bio\, Lyell\, among others promise to usher in the next era of innovation. The science is established. The patient benefits are real.  The possibilities are endless. \nPart 1 Focus:\n•  Where we are now—FDA Approved Therapies\n•  How we got here—the science in a broad international sense but specifically highlighting Seattle’s history in the development of cellular therapies.\n•  The history of how these therapies have made it to market. Special challenges this new technology had to face such as manufacturing.\n•  What therapies are currently on the market\n•  Special focus on how current therapies are putting more patients on a path to a cure \nPricing: \n$25 in-person (includes lunch and beverages)\n$10 virtual via zoom
URL:https://scienceinseattle.com/event/cellular-therapy-series-part-i-how-engineered-cellular-therapies-are-reshaping-medicine-2/
LOCATION:Online
ORGANIZER;CN="Life Science Washington":MAILTO:kaitlyn@lifesciencewa.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20220504T120000
DTEND;TZID=America/Vancouver:20220504T130000
DTSTAMP:20260613T094523
CREATED:20220411T165417Z
LAST-MODIFIED:20220411T165417Z
UID:26840-1651665600-1651669200@scienceinseattle.com
SUMMARY:Cellular Therapy Series Part I: How Engineered Cellular Therapies are Reshaping Medicine
DESCRIPTION:Part 1: Wednesday\, May 4\, 2022\, 12:00 – 1:00 PM\nPart 2: Wednesday\, September 14\, 2022\, 12:00 – 1:00 PM \nCellular therapies are reshaping the therapeutic landscape\, representing one of the highest growth sectors for FDA IND applications\, spurring some of the most recognized young companies\, producing several high-value cancer drugs\, and transforming lives. The Seattle area has led the development from the start with seminal work by Dendreon\, bringing to market the first FDA-approved immunotherapy made from a patient’s own immune cells (Provenge)\, as well as pioneering advances in chimeric antigen receptor (CAR) T cell therapy by the Hutch\, Seattle Children’s Research Institute and Juno Therapeutics. Today the region remains at the forefront\, supporting the development and launch of two commercially available CAR T cell products\, Breyanzi (Juno/Celgene/Bristol Myers Squibb) and Abecma (2seventy bio (formerly bluebird bio)/Celgene/Bristol Myers Squibb)\, and delivering innovative cell therapies to put more patients on the path to a cure. Young cellular therapy companies with roots in Seattle such as\, Sana\, 2seventy bio\, Umoja\, GentiBio\, Notch Therapeutics\, Century Therapeutics\, Gilead\, Sonoma Bio\, Lyell\, among others promise to usher in the next era of innovation. The science is established. The patient benefits are real.  The possibilities are endless. \nPart 1 Focus:\n•  Where we are now—FDA Approved Therapies\n•  How we got here—the science in a broad international sense but specifically highlighting Seattle’s history in the development of cellular therapies.\n•  The history of how these therapies have made it to market. Special challenges this new technology had to face such as manufacturing.\n•  What therapies are currently on the market\n•  Special focus on how current therapies are putting more patients on a path to a cure \nPricing: \n$25 in-person (includes lunch and beverages)\n$10 virtual via zoom
URL:https://scienceinseattle.com/event/cellular-therapy-series-part-i-how-engineered-cellular-therapies-are-reshaping-medicine-3/
LOCATION:Online
ORGANIZER;CN="Life Science Washington":MAILTO:kaitlyn@lifesciencewa.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220504T120000
DTEND;TZID=UTC:20220504T130000
DTSTAMP:20260613T094523
CREATED:20220502T180628Z
LAST-MODIFIED:20220502T180628Z
UID:17766-1651665600-1651669200@scienceinseattle.com
SUMMARY:Biostatistics Seminar Series
DESCRIPTION:The Fred Hutch Biostatistics Program hosts seminars featuring presentations by Fred Hutch and outside scientists to share their latest developments and recent research. Each seminar includes an hour-long presentation and discussion during which speakers showcase their work and findings. \nThis seminar will be held on Zoom due to the COVID-19 pandemic. \nPRESENTER: Andy Ni\, Ph.D.\n\n“Contrast Weighted Learning for Robust Optimal Treatment Regimen Estimation”\n\n\nPersonalized medicine aims to tailor medical decisions based on patient-specific characteristics. Advances in data capturing techniques such as electronic health records dramatically increase the availability of comprehensive patient profiles\, promoting the rapid development of optimal treatment rule (OTR) estimation methods. An archetypal OTR estimation approach is the outcome weighted learning\, where OTR is determined under a weighted classification framework with clinical outcomes as the weights. Although outcome weighted learning has been extensively studied and extended\, existing methods are susceptible to irregularities of outcome distributions such as outliers and heavy tails.  Methods that involve modeling of the outcome are also sensitive to model misspecification. We propose a contrast weighted learning (CWL) framework that exploits the flexibility and robustness of contrast functions to enable robust OTR estimation for a wide range of clinical outcomes. The novel value function in CWL only depends on the pairwise contrast of clinical outcomes between patients irrespective of their distributional features and supports. The Fisher consistency and convergence rate of the estimated decision rule via CWL are established. We illustrate the superiority of the proposed method under finite samples using comprehensive simulation studies with ill-distributed continuous outcomes and ordinal outcomes. We apply the CWL method to two datasets from clinical trials on idiopathic pulmonary fibrosis and COVID-19 to demonstrate its real-world application.
URL:https://scienceinseattle.com/event/biostatistics-seminar-series-9/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220504T120000
DTEND;TZID=UTC:20220504T130000
DTSTAMP:20260613T094523
CREATED:20220502T180628Z
LAST-MODIFIED:20220502T180628Z
UID:25889-1651665600-1651669200@scienceinseattle.com
SUMMARY:Biostatistics Seminar Series
DESCRIPTION:The Fred Hutch Biostatistics Program hosts seminars featuring presentations by Fred Hutch and outside scientists to share their latest developments and recent research. Each seminar includes an hour-long presentation and discussion during which speakers showcase their work and findings. \nThis seminar will be held on Zoom due to the COVID-19 pandemic. \nPRESENTER: Andy Ni\, Ph.D.\n\n“Contrast Weighted Learning for Robust Optimal Treatment Regimen Estimation”\n\n\nPersonalized medicine aims to tailor medical decisions based on patient-specific characteristics. Advances in data capturing techniques such as electronic health records dramatically increase the availability of comprehensive patient profiles\, promoting the rapid development of optimal treatment rule (OTR) estimation methods. An archetypal OTR estimation approach is the outcome weighted learning\, where OTR is determined under a weighted classification framework with clinical outcomes as the weights. Although outcome weighted learning has been extensively studied and extended\, existing methods are susceptible to irregularities of outcome distributions such as outliers and heavy tails.  Methods that involve modeling of the outcome are also sensitive to model misspecification. We propose a contrast weighted learning (CWL) framework that exploits the flexibility and robustness of contrast functions to enable robust OTR estimation for a wide range of clinical outcomes. The novel value function in CWL only depends on the pairwise contrast of clinical outcomes between patients irrespective of their distributional features and supports. The Fisher consistency and convergence rate of the estimated decision rule via CWL are established. We illustrate the superiority of the proposed method under finite samples using comprehensive simulation studies with ill-distributed continuous outcomes and ordinal outcomes. We apply the CWL method to two datasets from clinical trials on idiopathic pulmonary fibrosis and COVID-19 to demonstrate its real-world application.
URL:https://scienceinseattle.com/event/biostatistics-seminar-series-9-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20220504T120000
DTEND;TZID=UTC:20220504T130000
DTSTAMP:20260613T094523
CREATED:20220502T180628Z
LAST-MODIFIED:20220502T180628Z
UID:26854-1651665600-1651669200@scienceinseattle.com
SUMMARY:Biostatistics Seminar Series
DESCRIPTION:The Fred Hutch Biostatistics Program hosts seminars featuring presentations by Fred Hutch and outside scientists to share their latest developments and recent research. Each seminar includes an hour-long presentation and discussion during which speakers showcase their work and findings. \nThis seminar will be held on Zoom due to the COVID-19 pandemic. \nPRESENTER: Andy Ni\, Ph.D.\n\n“Contrast Weighted Learning for Robust Optimal Treatment Regimen Estimation”\n\n\nPersonalized medicine aims to tailor medical decisions based on patient-specific characteristics. Advances in data capturing techniques such as electronic health records dramatically increase the availability of comprehensive patient profiles\, promoting the rapid development of optimal treatment rule (OTR) estimation methods. An archetypal OTR estimation approach is the outcome weighted learning\, where OTR is determined under a weighted classification framework with clinical outcomes as the weights. Although outcome weighted learning has been extensively studied and extended\, existing methods are susceptible to irregularities of outcome distributions such as outliers and heavy tails.  Methods that involve modeling of the outcome are also sensitive to model misspecification. We propose a contrast weighted learning (CWL) framework that exploits the flexibility and robustness of contrast functions to enable robust OTR estimation for a wide range of clinical outcomes. The novel value function in CWL only depends on the pairwise contrast of clinical outcomes between patients irrespective of their distributional features and supports. The Fisher consistency and convergence rate of the estimated decision rule via CWL are established. We illustrate the superiority of the proposed method under finite samples using comprehensive simulation studies with ill-distributed continuous outcomes and ordinal outcomes. We apply the CWL method to two datasets from clinical trials on idiopathic pulmonary fibrosis and COVID-19 to demonstrate its real-world application.
URL:https://scienceinseattle.com/event/biostatistics-seminar-series-9-3/
LOCATION:Online
END:VEVENT
END:VCALENDAR